MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/04/6601-56-69$20.00
Mol Pharmacol 66:56-69, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morris, K. D. W.
Right arrow Articles by Amin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morris, K. D. W.
Right arrow Articles by Amin, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*L-SERINE

Insight into the Mechanism of Action of Neuroactive Steroids

Kendall D. W. Morris , and Jahanshah Amin

Departments of Pharmacology & Therapeutics and Physiology & Biophysics, College of Medicine, University of South Florida

Rho1 receptor-channels ({rho}1Rs) are GABA-gated chloride channels that exhibit slow kinetics, little desensitization, and inert pharmacology to most anesthetics, except for neuroactive steroids (NSs). NSs differentially modulate {rho}1Rs dependent on the steric arrangement of the hydrogen atom at the fifth carbon position. In particular, the NS allotetrahydrodeoxycorticosterone (5{alpha}-THDOC) potentiates, whereas 5{beta}-pregnane-3{alpha}-ol-20-one (pregnanolone) and 5{beta}-dihydroprogesterone (5{beta}-DHP) inhibit {rho}1 GABA currents. Here, we used Xenopus laevis oocytes expressing {rho}1Rs as a model system to study the mechanism of NS modulation. The second transmembrane residue, Ile307, was mutated to 16 amino acids. Subsequent testing of these mutants with 5{alpha}- and 5{beta}-NSs, at equivalent GABA activity, showed the following paradigm. For 5{beta}-DHP, Ile307 mutation either altered the degree of inhibition or entirely reversed the direction of modulation, rendering 5{beta}-DHP a potentiator. Dependent on the mutation, pregnanolone remained an inhibitor, transformed into a potentiator, or converted to inhibitor and potentiator based on concentration. The extent of mode reversal for both 5{beta} compounds showed a correlation with the side-chain hydrophilicity of the 307 residue. In contrast, Ile307 substitutions did not alter the direction of modulation for 5{alpha}-THDOC but caused a significant increase in the level of potentiation. Paradoxical to their impact on the mode and/or the degree of modulation, none of the mutations altered the concentration range producing the response significantly for any of the above NSs. Moreover, preincubation of Ile307 mutants with 5{alpha} or 5{beta} alone produced an equivalent effect on the activation time course. Based on the above data, a universal model is presented wherein anesthetic compounds like NSs can potentiate or inhibit the activity of ligand-gated ion channels distinct from interaction with alternative binding sites.


Received December 18, 2003; accepted April 1, 2004.

Address correspondence to: Jahanshah Amin, PhD, University of South Florida, College of Medicine, Departments of Pharmacology and Therapeutics, MDC Box 9, 12901 Bruce B. Downs Blvd., Tampa, FL 33612. E-mail: jamin{at}hsc.usf.edu




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
V. Twede, A. L. Tartaglia, D. F. Covey, and B. A. Bamber
The Neurosteroids Dehydroepiandrosterone Sulfate and Pregnenolone Sulfate Inhibit the UNC-49 GABA Receptor through a Common Set of Residues
Mol. Pharmacol., November 1, 2007; 72(5): 1322 - 1329.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. Li, X. Jin, D. F. Covey, and J. H. Steinbach
Neuroactive Steroids and Human Recombinant {rho}1 GABA Receptors
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 236 - 247.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
S. H. Hadley and J. Amin
Rat {alpha}6beta2{delta} GABAA receptors exhibit two distinct and separable agonist affinities
J. Physiol., June 15, 2007; 581(3): 1001 - 1018.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Chen, K. Reilly, and Y. Chang
Evolutionarily Conserved Allosteric Network in the Cys Loop Family of Ligand-gated Ion Channels Revealed by Statistical Covariance Analyses
J. Biol. Chem., June 30, 2006; 281(26): 18184 - 18192.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
W. Li, D. F. Covey, J.-M. Alakoskela, P. K. J. Kinnunen, and J. H. Steinbach
Enantiomers of Neuroactive Steroids Support a Specific Interaction with the GABA-C Receptor as the Mechanism of Steroid Action
Mol. Pharmacol., June 1, 2006; 69(6): 1779 - 1782.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
P. Li, D. F. Covey, J. H. Steinbach, and G. Akk
Dual Potentiating and Inhibitory Actions of a Benz[e]indene Neurosteroid Analog on Recombinant {alpha}1beta2{gamma}2 GABAA Receptors
Mol. Pharmacol., June 1, 2006; 69(6): 2015 - 2026.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. S. Miller, H. M. A. Da Silva, and T. G. Smart
Molecular Basis for Zinc Potentiation at Strychnine-sensitive Glycine Receptors
J. Biol. Chem., November 11, 2005; 280(45): 37877 - 37884.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics